Lynx1 Capital Management LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001910456

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 31 positions · Total reported value $646.09M · Top-10 concentration 97.9% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 30.3% · 6 new · 2 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -15.3% · vs SPY -17.4% · Prev Value $865.53M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -5.1% · vs SPY -7.2% · Latest Value $646.09M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Lynx1 Capital Management LP disclosed 31 equity positions with a combined reported value of $646.09M. The filing implies a focused portfolio: its ten largest positions account for 97.9% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were GHRS ($311.42M), CGEM ($137.59M), STOK ($101.30M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Lynx1 Capital Management LP opened 6 new positions, trimmed 2 and fully exited 2, a turnover rate of 30.3% of positions. The portfolio's overlap with the prior quarter was 76% of names.

The largest new positions opened in Q3 2026 were KZIA ($2.17M), SRZN ($643.60K), DARE ($495.44K).

Of the 2 positions fully exited versus the prior quarter, the largest were CGON ($2.23M), VYNE ($1.06M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • KZIA KAZIA THERAPEUTICS LTD · $2.17M
  • SRZN SURROZEN INC · $643.60K
  • DARE YARROW BIOSCIENCE INC · $495.44K
  • IMCR IMMUNOCORE HLDGS PLC · $433.15K
  • DYN DYNE THERAPEUTICS INC · $402.75K
  • PRME PRIME MEDICINE INC · $137.47K

Fully Exited (vs previous quarter)

  • CGON CG ONCOLOGY INC · prev qtr: $2.23M
  • VYNE YARROW BIOSCIENCES INC · prev qtr: $1.06M

Insider Transactions (Form 4)

Latest Lynx1 Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-26 Buy Korro Bio, Inc. 25,124 $11.75 SEC filing
2026-10-23 Buy Korro Bio, Inc. 2,510 $12.11 SEC filing
2026-10-22 Buy Korro Bio, Inc. 40,000 $11.04 SEC filing
2026-10-22 Buy Korro Bio, Inc. 12,175 $9.68 SEC filing
2026-08-10 Buy Korro Bio, Inc. 1,462 $13.19 SEC filing
2026-08-06 Buy Korro Bio, Inc. 5,222 $11.40 SEC filing
2026-06-25 Buy Passage BIO, Inc. 50,055 $4.12 SEC filing

All insider transactions →

Fund Profile

Lynx1 Capital Management LP, based in Dorado, PR, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 31 positions worth $646.09M in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: DORADO, PR, United States
  • SEC registration: 801-127585 (status: Approved), registered 2023-04-05
  • Regulatory AUM (Form ADV): $626.68M as of 2026-10-07
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds

Portfolio Structure

  • 31 positions · $646.09M reported value (Q3 2026)
  • Top 10 holdings = 97.9% of reported value
  • Largest position: GHRS (GH RESEARCH PLC) at 48.2%
  • Average position size: $20.84M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 6 new, 5 added, 2 reduced, 2 exited
  • 18 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to biotech/healthcare (all holdings in Health Care), with significant new positions in gene therapy (DTIL, PRQR) and a major reduction in Agios Pharmaceuticals (AGIO), suggesting a bullish stance on emerging gene-editing platforms but bearish on metabolic disease therapeutics. 2. Key moves: - Added: DTIL (+190.2% shares), PRQR (+199.6% shares), CCCC (+2.8% shares). - Reduced: AGIO (-86.1% shares), STOK (-3.5% shares). 3. Portfolio structure: Highly active, concentrated (top-10 holdings = 97.4%), and deeply biased toward healthcare (100%), with high risk (small-cap biotech, volatile stocks). 4. Per-holding one-liner: - GHRS: Gene therapy research (GH Research PLC). - CGEM: Cancer therapeutics (Cullinan Therapeutics). - STOK: Neuroscience gene therapy (Stoke Therapeutics). - CCCC: Neurodegenerative disease drugs (C4 Therapeutics). - DTIL: Gene editing (Precision Biosciences). - AGIO: Cancer metabolism drugs (Agios Pharmaceuticals). - KRRO: Cell/gene therapy (Korro Bio). - NEUP: Neurodegenerative disease drugs (Neuphoria Therapeutics). - PASG: CNS gene therapy (Passage Bio). - PRQR: RNA-based therapeutics (ProQR Therapeutics). 5. Style summary: Aggressive biotech fund doubling down on gene-editing platforms while cutting exposure to metabolic disease plays.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 11:32

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 13.26M $311.42M 48.20%
48.20%
Hold
2 8.96M $137.59M 21.30%
21.30%
Hold
3 3.90M $101.30M 15.68%
15.68%
Reduce
4 7.53M $25.08M 3.88%
3.88%
Add
5 2.76M $17.27M 2.67%
2.67%
Add
6 472.61K $15.71M 2.43%
2.43%
Reduce
7 1.54M $15.31M 2.37%
Form 4 · 4 →
2.37%
Hold
8 875.33K $3.12M 0.48%
0.48%
Hold
9 673.76K $3.03M 0.47%
0.47%
Hold
10 1.56M $2.59M 0.40%
0.40%
Add
11 8.02M $2.52M 0.39%
0.39%
Hold
12 225.80K $2.17M 0.34%
0.34%
New
13 1.80M $1.94M 0.30%
0.30%
Hold
14 278.61K $1.77M 0.27%
0.27%
Add
15 20.00K $643.60K 0.10%
0.10%
New
16 71.26K $625.69K 0.10%
0.10%
Add
17 657.79K $606.68K 0.09%
0.09%
Hold
18 22.00K $495.44K 0.08%
0.08%
New
19 18.19K $453.94K 0.07%
0.07%
Hold
20 14.30K $433.15K 0.07%
0.07%
New
21 25.00K $402.75K 0.06%
0.06%
New
22 559.47K $332.21K 0.05%
0.05%
Hold
23 11.66K $240.97K 0.04%
0.04%
Hold
24 21.25K $228.81K 0.04%
0.04%
Hold
25 61.59K $219.87K 0.03%
0.03%
Hold
26 10.10K $154.83K 0.02%
0.02%
Hold
27 45.00K $137.47K 0.02%
0.02%
New
28 30.80K $113.34K 0.02%
0.02%
Hold
29 10.00K $91.00K 0.01%
0.01%
Hold
30 16.03K $89.76K 0.01%
0.01%
Hold
31 20.00K $1.20K 0.00%
0.00%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 90% R 90% F1 90% (modelled on 2026-Q2; 9/10 hit)

Historical Backtest (11 quarters)

Avg precision 80% · recall 80% · F1 80% · avg rank error 1.7 · Top-10 turnover 20%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 90% 90% 90% ALPN · CABA · MRUS · TCRX · CCCC · STOK · AUTL · GHRS · KNTE · SLN ALPN · MRUS · STOK · TCRX · CABA · GHRS · CCCC · SLN · AUTL · PASG
2024-Q2 70% 70% 70% ALPN · MRUS · STOK · TCRX · GHRS · CABA · CCCC · SLN · AUTL · PASG MRUS · STOK · GHRS · CCCC · TCRX · CGEM · ALLO · LBPH · PASG · CABA
2024-Q3 80% 80% 80% STOK · MRUS · GHRS · CCCC · TCRX · CGEM · ALLO · PASG · LBPH · CABA MRUS · STOK · CCCC · GHRS · TCRX · ALLO · CGEM · PASG · IBIO · CRBU
2024-Q4 80% 80% 80% MRUS · STOK · CCCC · GHRS · TCRX · ALLO · CGEM · PASG · IBIO · CRBU MRUS · STOK · GHRS · CCCC · ALLO · TCRX · CGEM · KROS · PASG · ALLK
2025-Q1 70% 70% 70% MRUS · STOK · GHRS · ALLO · CCCC · CGEM · TCRX · KROS · PASG · ALLK GHRS · MRUS · PTGX · STOK · CGEM · ALLO · CCCC · TCRX · DTIL · IBIO
2025-Q2 90% 90% 90% GHRS · MRUS · PTGX · STOK · CGEM · ALLO · CCCC · TCRX · DTIL · IBIO MRUS · GHRS · STOK · PTGX · CGEM · ALLO · TCRX · CCCC · DTIL · PASG
2025-Q3 90% 90% 90% GHRS · MRUS · STOK · PTGX · CGEM · ALLO · TCRX · CCCC · DTIL · PASG MRUS · STOK · GHRS · PTGX · CGEM · CCCC · TCRX · DTIL · ADCT · PASG
2025-Q4 60% 60% 60% MRUS · STOK · GHRS · PTGX · CGEM · CCCC · TCRX · DTIL · ADCT · PASG STOK · GHRS · CGEM · DNLI · CCCC · XNCR · IMTX · TCRX · PASG · KRRO
2026-Q1 80% 80% 80% STOK · GHRS · CGEM · DNLI · CCCC · XNCR · IMTX · TCRX · PASG · KRRO STOK · GHRS · CGEM · AGIO · DNLI · CCCC · KRRO · TCRX · XNCR · DTIL
2026-Q2 80% 80% 80% GHRS · STOK · CGEM · AGIO · DNLI · KRRO · CCCC · TCRX · XNCR · DTIL GHRS · CGEM · STOK · AGIO · CCCC · KRRO · TCRX · DTIL · NEUP · PASG
2026-Q3 ★ 90% 90% 90% GHRS · CGEM · AGIO · STOK · CCCC · KRRO · TCRX · DTIL · NEUP · PASG GHRS · CGEM · STOK · CCCC · DTIL · AGIO · KRRO · NEUP · PASG · PRQR

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings1 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-12.53%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+4.48%vs benchmark
Barra annualised vol65.7%Model estimate
Realised vol50.4%Annualised in window
Weighted beta1.37Raw exposure
Factor / specific risk28% / 72%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-16Lynx1 Capital Management LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-12.53%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+4.48%Portfolio − benchmark
Arithmetic return sum-11.73%Difference vs compounded is the cross term
Weighted raw beta1.37Weighted holding betas
Realised volatility (annualised)50.43%Daily returns in window
Barra model volatility (annualised)65.73%Factor + specific
Factor share of variance27.7%Barra factors
Specific share of variance72.3%Stock residuals
Reported value$240,97113F long US equity

2. Return attribution

The -11.73% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -1.55% -13.2%
Momentum & Growth 3 -4.96% -42.3%
Volatility & Tail Risk 7 +7.58% 64.6%
Industry 12 +6.98% 59.5%
Specific 1 -19.78% -168.6%
Return attribution (style + industry, %)-7.5-3.8+0.0+3.8+7.5Amihud Illiquidity-1.23Turnover-1.46Beta+2.30Growth-2.47Leverage (Downside Vol)-3.07Non-linear Size+3.10Size+3.23Momentum-3.49Kurtosis+4.61Residual Volatility+4.96Mid Cap-5.17Skewness+6.35Historical Volatility-6.65Health Care+6.98
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +1.00 +6.98% +6.98% 59.5%
Skewness Style -1.44 -4.39% +6.35% 54.1%
Residual Volatility Style +1.51 +3.29% +4.96% 42.3%
Kurtosis Style +0.61 +7.51% +4.61% 39.3%
Size Style -1.66 -1.95% +3.23% 27.6%
Non-linear Size Style +3.07 +1.01% +3.10% 26.4%
Beta Style +0.52 +4.44% +2.30% 19.6%
Short-term Reversal Style +1.14 +0.87% +0.99% 8.5%
Max Drawdown Style +0.52 -1.76% -0.92% -7.8%
Amihud Illiquidity Style +2.75 -0.45% -1.23% -10.4%
Turnover Style +0.30 -4.80% -1.46% -12.4%
Growth Style -1.42 +1.75% -2.47% -21.1%
Leverage (Downside Vol) Style +1.79 -1.71% -3.07% -26.2%
Momentum Style +0.87 -4.00% -3.49% -29.7%
Mid Cap Style +2.67 -1.94% -5.17% -44.1%
Historical Volatility Style +0.47 -14.00% -6.65% -56.7%
Specific Specific — — -19.78% -168.6%

3. Risk attribution

Annualised volatility is 65.73%; factor risk explains 27.7% of variance and specific risk 72.3%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-78.1-39.0+0.0+39.0+78.1Growth-0.77Leverage (Downside Vol)+0.70Historical Volatility+0.76Momentum+0.89Non-linear Size+1.00Max Drawdown+1.00Skewness+1.25Residual Volatility+1.60Amihud Illiquidity+1.86Beta+2.31Size+3.85Mid Cap+6.17Health Care+6.68Specific+72.30
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 72.3% +47.52% 47.5%
Health Care Industry +1.00 6.7% +4.39% 4.4%
Mid Cap Style +2.67 6.2% +4.06% 4.1%
Size Style -1.66 3.9% +2.53% 2.5%
Beta Style +0.52 2.3% +1.52% 1.5%
Amihud Illiquidity Style +2.75 1.9% +1.22% 1.2%
Residual Volatility Style +1.51 1.6% +1.05% 1.1%
Skewness Style -1.44 1.2% +0.82% 0.8%
Non-linear Size Style +3.07 1.0% +0.66% 0.7%
Max Drawdown Style +0.52 1.0% +0.66% 0.7%
Momentum Style +0.87 0.9% +0.59% 0.6%
Historical Volatility Style +0.47 0.8% +0.50% 0.5%
Leverage (Downside Vol) Style +1.79 0.7% +0.46% 0.5%
Short-term Reversal Style +1.14 0.5% +0.30% 0.3%
Kurtosis Style +0.61 -0.2% -0.14% -0.1%
Growth Style -1.42 -0.8% -0.50% -0.5%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-2.1-0.70.72.13.5Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.66 +2.10 -3.76
Non-linear Size +3.07 +1.68 +1.39
Mid Cap +2.67 +0.13 +2.54
Beta +0.52 +1.29 -0.78
Momentum +0.87 +0.72 +0.16
Short-term Reversal +1.14 -0.64 +1.78
Residual Volatility +1.51 -0.40 +1.91
Historical Volatility +0.47 +0.86 -0.39
Liquidity -0.09 +0.11 -0.20
Amihud Illiquidity +2.75 +1.16 +1.60
Turnover +0.30 +0.21 +0.10
Growth -1.42 +0.58 -2.00
Leverage (Downside Vol) +1.79 +0.14 +1.65
Skewness -1.45 +0.24 -1.68
Kurtosis +0.61 +0.21 +0.40
Max Drawdown +0.52 -0.08 +0.60

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Health Care 100.0% 1.7% -12.53% +8.29% +24.98% -0.36% -20.46% -12.67%
Total +23.98% +15.48% -36.30% +3.17%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
DNLI DENALI THERAPEUTICS INC Health Care 100.00% -12.53% -12.53% Hold
Contribution rank Symbol Sector Weight Return Contribution
1 DNLI Health Care 100.00% -12.53% -12.53%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -12.53%, versus -17.01% for the QQQ synthetic benchmark — an excess of +4.48%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +6.98%, Skewness +6.35%, Residual Volatility +4.96%; the largest drags came from Historical Volatility -6.65%, Mid Cap -5.17%, Momentum -3.49%. Specific (stock-level) return contributed -19.78%.
  3. Risk attribution: Barra model volatility is 65.73% annualised; factor risk explains 28% of variance and specific risk 72%. The largest factor risk sources are Health Care 6.7%, Mid Cap 6.2%, Size 3.9%.
  4. Style tilt: size -1.66, momentum +0.87, volatility +0.47, liquidity -0.09; the weighted raw beta is 1.37. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.48% and interaction -36.30%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Lynx1 Capital Management LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Lynx1 Capital Management LP reported 31 equity positions worth $646.09M in aggregate; its largest disclosed positions were GHRS ($311.42M), CGEM ($137.59M), STOK ($101.30M).

How large is Lynx1 Capital Management LP's portfolio?

Lynx1 Capital Management LP reported $646.09M of long equity holdings across 31 positions as of 2026-Q3. Top-10 holdings account for 97.9% of reported value.

What is Lynx1 Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/lynx1-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →